A new Covid variant has been found in the UK but experts say it’s too soon to know if it is more transmissible than previous strains.
The UK Health Security Agency (UKHSCA) said it was studying XE - a mutation of the BA.1 and BA.2 Omicron strains, referred to as a "recombinant".
As if the border crisis isn’t damaging enough, with 2.5 million illegal migrants having crossed into the United States since Joe Biden took office, now the administration is going to make it exponentially worse by unwinding the last Trump-era restriction.
The Title 42 policy, implemented by the Trump administration during the pandemic to allow border officials to quickly expel migrants on public health grounds, will be terminated next month, the CDC announced Friday.
Title 42 was the last tool that border officials had to stem the flow of illegal migration from more than 150 countries across the southern border. Now they are anticipating a doubling or tripling of numbers, to as many as 18,000 a day.
We know what that means: more secret migrant flights fanning out from the southern border to a town near you.
Already, charter flights to White Plains airport in Westchester have started again, after a hiatus following The Post’s report last October revealing migrant planes landing in the middle of the night several times a week and unloading hundreds of migrants, claimed to be children, to be spirited away on buses to locations around New York and neighboring states.
A World Atlantic Airways plane thought to be bringing illegal migrants from El Paso, Texas, via Oklahoma City, Okla., landed at White Plains airport at 11:13 p.m. Sunday.
Unlike when The Post observed migrant flights last October, this plane was hidden on the far side of the tarmac, outside Ross Aviation East, after it landed so it was not possible to see passengers alighting.
But, as before, there were three charter buses, which met the plane and left around 12:20 a.m.
The buses traveled through White Plains, heading west on Interstate 287 at 70 miles an hour before splitting up. Two headed south toward New York City and one headed north toward Albany.
Unlike last year, the planes that have been landing at White Plains the last few weeks have been arriving before the airport’s midnight curfew, and there are fewer each week. They are stopping en route, in cities like Houston, Texas, and Oklahoma City, as opposed to Jacksonville, Fla., where The Post observed them last year disgorging migrants.
Publicly available flight data show World Atlantic Airways charter planes began landing again in White Plains in late February.
On February 25, March 11, March 19 and March 21, World Atlantic Airways flights from El Paso flew to White Plains via Houston, arriving between 7:59 p.m. and 9:21 p.m.
On March 4 and March 26, World Atlantic Airways planes flew from El Paso to White Plains via Oklahoma City, arriving at 9:25 p.m. and 9:33 p.m.
It is not known who was on board, but these are the same McDonnell Douglas MD-83 aircraft with the same registration numbers that were chartered by the Department of Health and Human Services and were observed by The Post flying illegal migrant minors into White Plains last year.
It is not just White Plains. Migrant flights from the border are traveling all over the country, as the administration tries to manage the deluge at the border by spreading the problem far and wide, turning every state into a border state.
With the end of Title 42, already record numbers are set to explode.
Even moderate Democrats think the move is insane. Sen. Joe Manchin of West Virginia and Sens. Mark Kelly and Kyrsten Sinema of Arizona have condemned the plan to nix Title 42.
Manchin described it as “a frightening decision … Title 42 has been an essential tool in combating the spread of COVID-19 and controlling the influx of migrants at our southern border.
“We are already facing an unprecedented increase in migrants this year, and that will only get worse if the Administration ends the Title 42 policy. We are nowhere near prepared to deal with that influx.”
Already, since President Biden dismantled Trump-era border restrictions on his first day in office, the number of illegal migrants who have entered the US is the equivalent of the fifth-largest city in the nation. By the time the midterms roll around, we will have another 5 million.
That’s at least 7 million total, the equivalent of the second-largest city in the country. Almost the size of New York City. It’s like importing the entire population of Libya.
And from next month, that’s the number who will enter every year unless someone wrests control of the border from the cartels.
By the time the next presidential election rolls around, in 2024, the number of Biden illegals will be over 20 million at these rates. That’s a 6% population increase over Biden’s term in illegal migration alone, against a backdrop of rampant inflation.
How do we house and feed such a horde? How do hospitals, schools and jails cope with this unheralded influx with no planning or preparation?
This is Biden’s biggest disaster, and there have been a few.
https://nypost.com/2022/04/04/biden-opens-the-title-42-gates/
New Capability Enables Individuals Identified as High-Risk by Participating Health Plans to Access Screening through a Quest Diagnostics Site
Builds on Quest's Extended Care Services to Improve Care Quality and Outcomes in Diabetes and Other Chronic Diseases
https://finance.yahoo.com/news/quest-diagnostics-adds-diabetic-retinopathy-125500374.html
Healios has announced feedback received from the PMDA after recent consultation meetings to obtain guidance and advice pertaining to its application for MultiStem approval for ARDS, an orphan regenerative medicine program, on the basis of its Phase 2 ONE-BRIDGE study. The ONE-BRIDGE clinical trial was designed as a 30-patient, open label study, and demonstrated promising impact from MultiStem treatment on ventilator free days (VFD) and mortality. While the PMDA did not disagree with the efficacy and safety conclusions of the ONE-BRIDGE study, the PMDA advised Healios that additional supporting data is necessary for application for approval of MultiStem treatment for the ARDS indication. As a result of the guidance from the PMDA, Healios does not currently plan to apply for approval in Q2 2022. Healios will continue discussions with PMDA and work toward early application, and while it is undetermined at this time, it is expected that the application for approval is unlikely to take place in the current fiscal year.
Athersys is currently conducting its Phase 2/3 MACOVIA study, evaluating MultiStem treatment for ARDS patients, which includes patients diagnosed with ARDS due to COVID-19. The Company recently announced FDA approval to use product manufactured with its next generation bioreactor-based platform in the MACOVIA study.
https://finance.yahoo.com/news/athersys-reports-partner-healios-k-100000788.html
Results presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
Trial achieved primary reversal endpoint in older volunteers
Bentracimab was well tolerated in the Phase 2b trial, with no drug-related serious adverse events or thrombotic events reported
https://finance.yahoo.com/news/phasebio-announces-positive-results-phase-120000222.html
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has granted celiprolol Breakthrough Therapy designation (BTD) in the U.S. for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS).
BTD is a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on at least one clinically significant endpoint(s) over available therapy.
https://finance.yahoo.com/news/acer-therapeutics-edsivo-celiprolol-granted-123000439.html
Novartis said on Monday it was integrating its pharmaceuticals and oncology units into an innovative medicines (IM) business to simplify its structure, targeting savings of at least $1 billion by 2024.
"Integrating pharmaceuticals and oncology business units into an innovative medicines (IM) business with separate U.S. and international commercial organizations will increase focus, strengthen competitiveness and drive synergies," the Swiss pharmaceutical company said in a statement.
It said it expects selling, general and administrative savings of at least $1 billion to be fully embedded by 2024 as a result of these changes.
The company based in Basel appointed Marie-France Tschudin as president of innovative medicines international and chief commercial officer, and Victor Bulto as president of innovative medicines in the United States.
Steffen Lang will take over as president operations, while
Shreeram Aradhye becomes president global drug development and chief medical officer. Susanne Schaffert, Robert Weltevreden and John Tsai are leaving Novartis, the company said.
Value creation through these operational improvements should ensure at least 4% sales growth in constant currency through 2026. Novartis also expects to deliver at the high end of its IM margin guidance of high 30s in the medium term and 40% or more in the mid- to long-term.
https://finance.yahoo.com/news/novartis-integrates-pharmaceuticals-oncology-targets-051939311.html
